Ironwood Pharma Promotes Tammi Gaskins to Succeed CEO Tom McCourt

Dow Jones10-16

Ironwood Pharmaceuticals' Chief Commercial Officer Tammi Gaskins has been appointed to succeed Chief Executive Tom McCourt when he retires after 17 years at the biotechnology company.

Boston-based Ironwood said Gaskins will step into the role effective the start of 2027, when McCourt steps down as CEO while remaining a board member.

Chair Julie McHugh said Gaskins was selected because she is a proven leader with a deep understanding of the company's business, and has been key in returning the Linzess irritable bowel syndrome treatment to blockbuster status and growth this year.

Gaskins has served as chief commercial officer since January 2025. Having joined the company in July 2020, she was previously vice president of brand management.

McCourt joined Ironwood in 2009 as chief commercial officer and vice president of marketing and sales, and rose to president and interim CEO before taking on the role permanently in 2021.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment